HAMPSON v. United States

District Court, M.D. Georgia·Decided November 9, 2022·No. 5:19-cv-00266·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF GEORGIA MACON DIVISION TERESA ECKHARDT,1 Plaintiff, CIVIL ACTION NO. v. 5:19-cv-00266-TES UNITED STATES OF AMERICA, Defendant.

ORDER

This matter is before the Court on Defendant’s Motion to Exclude Plaintiff’s Expert Testimony. [Doc. 99]. For the reasons stated below, the Court DENIES Defendant’s motion. [Id.]. BACKGROUND On June 28, 2019, Plaintiff Teresa Eckhardt (“Plaintiff”) filed this action under the Federal Tort Claims Act against the United States for the wrongful death of her husband, Gary Eckhardt (“Mr. Eckhardt”), a Vietnam Veteran. [Doc. 3]. Because of his service, Mr. Eckhardt earned the right to receive medical treatment through the Department of Veterans Affairs (the “VA”). [Id. at ¶ 9]. He primarily received such

1 Sadly, Plaintiff died during the pendency of this action. As of today, Plaintiff’s counsel is in the process of assisting Tracy Fernelius to be appointed the administrator of Plaintiff’s estate, and Tracy Fernelius and Tami Hampson to be named successor co-administrators of Mr. Eckhardt’s estate. Fernelius is Plaintiff’s daughter, and Hampson is Mr. Eckhardt’s daughter. The Court held a hearing to discuss this matter on September 28, 2022. See [Doc. 107]. treatment at the VA Medical Center in Atlanta, Georgia, and the Carl Vinson VA Medical Center in Dublin, Georgia. [Id.]. In April 2003, medical professionals at the VA

Medical Center in Atlanta diagnosed Mr. Eckhardt with Hepatitis C. [Id. at ¶ 10]. Plaintiff ultimately claims that the VA’s failure to effectively treat Mr. Eckhardt’s Hepatitis C with available curative drug therapies caused his premature death. [Id. at

¶¶ 16, 18–28]. The Government filed its Answer on August 30, 2019. [Doc. 8]. The Court held an intense, five-day bench trial that started on August 9 and ended on August 16, 2022.2 See [Doc. 108]; [Doc. 109]; [Doc. 110]; [Doc. 111]; [Doc. 112].

Dr. Robert G. Gish was Plaintiff’s sole expert who testified at trial and provided expert testimony in preparation for the trial. See [Doc. 42]; [Doc. 109]. Plaintiff submitted Dr. Gish’s Affidavit [Doc. 3-2] when she initially filed her Complaint [Doc. 3] on June 28, 2019. The Court issued its Scheduling and Discovery Order [Doc. 10] on October 28,

2019.3 The Order imposed a deadline for Plaintiff to disclose the identity of any expert witness on or before January 27, 2020. [Doc. 10, p. 7]. On January 27, 2020, Plaintiff disclosed Dr. Gish as her sole expert and filed Dr. Gish’s expert report. [Doc. 42]. In

disclosing Dr. Gish as an expert witness on January 27, 2020, Plaintiff also produced a document titled “Expert Testimony Summary.” [Doc. 99-1]. The document listed one

2 The Court notes that the bench trial has not technically concluded, as it expects Tracy Fernelius will testify after she is officially substituted as the plaintiff in this case.

3 Upon consideration of the parties’ Joint Motion to Amend Scheduling and Discovery Order [Doc. 11], the Court amended the Scheduling and Discovery Order on November 6, 2019, as to deadlines for the expiration of fact discovery, dispositive motions, and Daubert motions. [Doc. 12]. case in which Dr. Gish was deposed within the previous four years: U.S. v. USPLabs, LLC, No. 3:15-cr-496-L (N.D. Tex. 2019). [Id.]; [Doc. 109, p. 147].

Discovery ended on August 17, 2021. [Doc. 78, p. 3]. The Court issued its Order for Pretrial Conference [Doc. 52] on January 24, 2022. The parties jointly submitted their proposed pretrial order on March 11, 2022, and appeared for the pretrial conference on

March 15, 2022. [Doc. 59]. Plaintiff did not supplement Dr. Gish’s report concerning his previous testimony at any point until the morning after Dr. Gish testified during trial. Plaintiff called Dr. Gish to testify during trial on August 10, 2022. See [Doc. 109].

During the Government’s cross-examination of Dr. Gish, he revealed that he had previously testified as an expert witness within the four years preceding his January 2020 disclosure as well as between his January 2020 disclosure and the 2022 pretrial conference. [Id.]. With Dr. Gish still on the stand, the United States represented to the

Court that Plaintiff had failed to comply with her expert disclosure and supplementation obligations under Rules 26(a)(2)(B) and 26(e)(2) given Dr. Gish’s sworn admission about his previous testimony as an expert witness. [Id. at pp. 146–150].

The Court noted that Plaintiff must still comply with the requirements of Rule 26. [Id. at p. 224]. Plaintiff concedes that she inadvertently omitted cases in which Dr. Gish testified in his expert report. See [Doc. 100]. However, Plaintiff addressed this mistake by giving

the Government’s counsel a document titled “Robert G. Gish—Legal Consults/Testimony,” the morning after Dr. Gish testified. [Doc. 99-2]; [Doc. 110, pp. 4– 6]. The Government asks the Court to strike Dr. Gish’s testimony as a sanction for

Plaintiff’s noncompliance with Rule 26, which would effectively mandate judgment in its favor. DISCUSSION

The Government argues that Plaintiff violated her discovery obligations under Federal Rules of Civil Procedure 26(a)(2)(B) and 26(e)(2). “Rule 26 mandates that an expert’s written report contain specific information—such as . . . a list of all cases in

which the expert testified at trial or by deposition in the preceding four years.” OFS Fitel, LLC v. Epstein, Becker & Green, P.C., 549 F.3d 1344, 1362 (11th Cir. 2008) (citing Fed. R. Civ. P. 26(a)(2)(B)). The expert disclosure requirement under Rule 26(a)(2)(B) “is intended to provide opposing parties reasonable opportunity to prepare for effective

cross examination and perhaps arrange for expert testimony from other witnesses.” Id. at 1362–63 (citations omitted). In addition to the requirements for disclosures under Rule 26(a)(2)(B), litigants are obligated to supplement their expert witness disclosures.

Rule 26(e)(2) states, “[f]or an expert whose report must be disclosed under Rule 26(a)(2)(B), the party’s duty to supplement extends both to information included in the report and to information given during the expert’s deposition. Any additions or changes to this information must be disclosed by the time the party’s pretrial

disclosures under Rule 26(a)(3) are due.” Fed. R. Civ. P. 26(e)(2). Federal Rule of Civil Procedure 37(c)(1) establishes the consequences for parties who fail to comply with Rule 26(a) or (e). According to Rule 37(c)(1), the Court may

impose appropriate sanctions if a party fails to: (1) make initial disclosures under Rule 26(a)(1); (2) make expert disclosures under Rule 26(a)(2); or (3) supplement such disclosures as required by Rule 26(e)(2). However, if the failure to disclose was

“substantially justified or is harmless,” then the party may still use that witness. See Fed. R. Civ. P. 37(c)(1); U.S. ex rel. Bibby v. Mortg. Invs. Corp., No. 1:12-CV-4020-AT, No. 1:17-CV-2884-AT, 2017 WL 8218975, at *4 (N.D. Ga. Aug. 25, 2017) (“Exclusion of expert

testimony is a drastic remedy . . .

Free access — add to your briefcase to read the full text and ask questions with AI

HAMPSON v. United States, (M.D. Ga. 2022).

HAMPSON v. United States (HAMPSON v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Florentino Prieto v. Manuel Malgor
361 F.3d 1313 (Eleventh Circuit, 2004)
Bearint Ex Rel. Bearint v. Dorel Juvenile Group, Inc.
389 F.3d 1339 (Eleventh Circuit, 2004)
United States v. Ronald Keith Brown
415 F.3d 1257 (Eleventh Circuit, 2005)
Reese v. Herbert
527 F.3d 1253 (Eleventh Circuit, 2008)
OFS FITEL, LLC v. Epstein, Becker and Green, PC
549 F.3d 1344 (Eleventh Circuit, 2008)
Foreman v. AMERICAN ROAD LINES, INC.
623 F. Supp. 2d 1327 (S.D. Alabama, 2008)
Teresa Taylor v. Mentor Worldwide, LLC
940 F.3d 582 (Eleventh Circuit, 2019)
Leathers v. Pfizer, Inc.
233 F.R.D. 687 (N.D. Georgia, 2006)